Alan Reyes Mondragón, Profesor at TecSalud del Tecnológico de Monterrey, shared a post on LinkedIn:
“The perioperative treatment of muscle-invasive bladder cancer is changing fast.
In just a few years we’ve moved from chemotherapy alone to chemo-immunotherapy and antibody–drug conjugates – and pathologic complete response (pCR) rates have climbed with each step: from ~36–42% (VESPER) to 55.8% with EV + pembrolizumab (KN-B15/EV-304).
Now SAKK 06/19 brings something unexpected: the return of intravesical BCG, combined with chemo-immunotherapy, reaching a 57% pCR (68% on central review in cystectomy patients).
The bigger shift may be the paradigm itself: a future where response and ctDNA/utDNA dynamics – not protocol alone – decide who proceeds to cystectomy and who can pursue bladder preservation.”
Other articles about bladder cancer.